We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-2.59%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$3.57B
AUM Growth
-$69.4M
Cap. Flow
+$212M
Cap. Flow %
5.95%
Top 10 Hldgs %
61.01%
Holding
66
New
4
Increased
9
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$70.7M
2
GPCR icon
Structure Therapeutics
GPCR
+$68.8M
3
CELC icon
Celcuity
CELC
+$58M
4
CGEM icon
Cullinan Oncology
CGEM
+$54.4M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$43M

Top Sells

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$116M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$44.6M
3
KURA icon
Kura Oncology
KURA
+$14.5M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$12.8M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$8.35M

Sector Composition

Rank Sector Weight
1 Healthcare 99.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
1
MoonLake Immunotherapeutics
MLTX
$1.61B
$956M 26.81%
21,751,284
– –
RVMD icon
2
Revolution Medicines
RVMD
$40.3B
$232M 6.51%
5,981,212
– –
KYMR icon
3
Kymera Therapeutics
KYMR
$8.72B
$154M 4.32%
5,161,801
– –
IONS icon
4
Ionis Pharmaceuticals
IONS
$8.76B
$152M 4.26%
3,186,376
+757,763
+31% +$31.1M
MIRM icon
5
Mirum Pharmaceuticals
MIRM
$6.73B
$149M 4.19%
4,370,024
– –
GHRS icon
6
GH Research
GHRS
$1.96B
$121M 3.4%
10,400,158
– –
PTGX icon
7
Protagonist Therapeutics
PTGX
$8.75B
$115M 3.22%
3,319,290
-436,700
-12% -$12.8M
CGEM icon
8
Cullinan Oncology
CGEM
$1.06B
$100M 2.81%
5,750,683
+2,553,982
+80% +$54.4M
OLMA icon
9
Olema Pharmaceuticals
OLMA
$1.03B
$98.9M 2.77%
9,135,893
– –
GPCR icon
10
Structure Therapeutics
GPCR
$3.46B
$97.7M 2.74%
2,487,762
+1,674,774
+206% +$68.8M
XOMA
11
DELISTED
Xoma
XOMA
$86.1M 2.41%
3,633,743
– –
KURA icon
12
Kura Oncology
KURA
$827M
$84M 2.36%
4,082,037
-704,256
-15% -$14.5M
FDMT icon
13
4D Molecular Therapeutics
FDMT
$539M
$82.3M 2.31%
3,922,413
– –
AXSM icon
14
Axsome Therapeutics
AXSM
$11.8B
$76.9M 2.15%
+955,000
New +$70.7M
CGON icon
15
CG Oncology
CGON
$6.29B
$76.3M 2.14%
2,417,885
+533,694
+28% +$18.5M
MRUS
16
DELISTED
Merus
MRUS
$75.7M 2.12%
1,279,049
+106,800
+9% +$5.17M
ACIU icon
17
AC Immune
ACIU
$233M
$75.2M 2.11%
18,834,936
+4,263,700
+29% +$14.1M
TYRA icon
18
Tyra Biosciences
TYRA
$1.95B
$74.5M 2.09%
4,661,194
– –
ETNB
19
DELISTED
89bio
ETNB
$60.6M 1.7%
7,568,479
+3,521,125
+87% +$31.4M
CELC icon
20
Celcuity
CELC
$4.29B
$56.8M 1.59%
+3,466,000
New +$58M
THRD
21
DELISTED
Third Harmonic Bio
THRD
$56.8M 1.59%
4,365,933
– –
AGIO icon
22
Agios Pharmaceuticals
AGIO
$1.93B
$51.3M 1.44%
+1,190,107
New +$43M
ZYME icon
23
Zymeworks
ZYME
$1.66B
$50M 1.4%
5,870,000
– –
EPIX
24
DELISTED
ESSA Pharma
EPIX
$46M 1.29%
8,748,629
– –
IDYA icon
25
IDEAYA Biosciences
IDYA
$3.47B
$40.8M 1.14%
1,162,306
– –
1
2 3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2024 Portfolio in Review

As of Q2 2024, BVF Inc held 66 positions worth $3.57B, down 1.9% from $3.64B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

BVF Inc deployed $212M of net new capital in Q2 2024, opening 4 new positions and adding to 9 existing holdings. Its largest new stake was Axsome Therapeutics: 955,000 shares worth $76.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Janux Therapeutics, an estimated $116M trimmed.

  • BVF Inc's largest Q2 2024 buy was Axsome Therapeutics: 955,000 shares worth $76.9M.
  • BVF Inc added most to Structure Therapeutics in Q2 2024, an estimated $68.8M increase.
  • BVF Inc's biggest Q2 2024 reduction was Janux Therapeutics, cutting an estimated $116M.
  • BVF Inc fully exited Syndax Pharmaceuticals in Q2 2024, selling an estimated $44.6M.
  • BVF Inc's ten largest holdings make up 61% of its $3.57B portfolio in Q2 2024.
  • BVF Inc opened 4 new positions and closed 6 in Q2 2024.
  • BVF Inc's portfolio value fell 1.9% quarter-over-quarter to $3.57B.

Based on BVF Inc's 13F filing for Q2 2024, filed 14 Aug 2024.